ONWARD Medical N.V.
ONWD.BRHealthcareLEI 9845007A2CC4C8BFSB80
At a glance
- Most recent filing on April 7, 2026 — a trade by Marver, Lawrence D.L. on Apr 2, 2026.
- Over the past 90 days: 0 open-market buys.
- This page shows 18 visible filings, of which 0 open-market buys, going back to December 20, 2021.
How the company itself measures up
Four components from the annual figures and the price series, compared with the other companies on the same date. Separate from the filing above, and separate from the question of whether this is a good moment.
On this measurement the company came out above 9% of the companies measured. That says something about the company's numbers, not about its share price.
As of Jul 31, 2026 · methodology 0.4.0
| Component | What is measured | Sub-score | Weight | Compared with |
|---|---|---|---|---|
| Quality | gross profit relative to total assets | 40% | all measured companies | |
| Valuation | operating profit relative to the value of the whole business | 34% | all measured companies | |
| Momentum | price return over twelve months, excluding the most recent month | 25% | all measured companies | |
| What goes to shareholders | dividends and share buybacks relative to market value | — | not measured — reweighted |
Labels on this measurement: Share count grew (12 months). These are notes about the data. Nothing is subtracted from the score, and it is not a warning about the company.
These figures only mean something in comparison: they take on meaning next to the other companies of that same date. See the full ranking →
Price history and buy moments
Every visible filing
What was filed, most recent first. On an award the register reports a price of 0 — nothing was paid — and then the Quantity column tells you how large the filing was.
| Reported | Filed by | Role | Category | Quantity | Amount |
|---|---|---|---|---|---|
| Apr 7, 2026 | Marver, Lawrence D.L. | CEO | Open-market sell | 152,759 | €499,522 |
| Jan 8, 2026 | Kiboro A. | Chief Financial Officer | Award | 200,000 | nothing paid |
| Jan 18, 2024 | Murphy J. | Chief Technology Officer | Award | 75,000 | nothing paid |
| Jan 24, 2023 | Bloch J. | Co-Founder | Administrative | 302,144 | nothing paid |
| Jan 24, 2023 | Bloch J. | Co-Founder | Administrative | 302,144 | nothing paid |
| Jan 6, 2023 | Murphy J. | Chief Technology Officer | Award | 165,000 | nothing paid |
| Jan 6, 2023 | Smith Weber L. | CFO | Award | 96,250 | nothing paid |
| Nov 29, 2022 | Murphy J. | Chief Technology Officer | Administrative | 381,926 | nothing paid |
| Nov 29, 2022 | Murphy J. | Chief Technology Officer | Administrative | 381,926 | nothing paid |
| Sep 30, 2022 | Smith Weber L. | CFO | Award | 50,000 | nothing paid |
| Dec 20, 2021 | Burkhanova R. | Global Human Resources Director | Award | 22,000 | nothing paid |
| Dec 20, 2021 | Dolan A. | Vice President Marketing | Award | 38,000 | nothing paid |
| Dec 20, 2021 | Cebotari D. | Chief of Staff | Award | 22,000 | nothing paid |
| Dec 20, 2021 | Murphy J. | Chief Technology Officer | Award | 86,000 | nothing paid |
| Dec 20, 2021 | Delattre V. | Vice President Business Development | Award | 38,000 | nothing paid |
| Dec 20, 2021 | Harari D. | Managing Director US | Award | 38,000 | nothing paid |
| Dec 20, 2021 | Jansen M. | Chief Financial Officer / Chief Operating Officer | Award | 42,000 | nothing paid |
| Dec 20, 2021 | Lambert H. | Vice President Clinical Regulatory Quality | Award | 38,000 | nothing paid |
Follow this company
Loading follow status…
The insider, quant and timing scores stand apart from one another and are meant as context. There is no threshold in them (“above such and such is worth buying”), we do not add them up into a single figure, and none of it is a recommendation. How they are calculated is in the methodology.